Your browser is no longer supported. Please, upgrade your browser.
CCXI ChemoCentryx, Inc. daily Stock Chart
CCXI [NASD]
ChemoCentryx, Inc.
Index- P/E- EPS (ttm)-1.10 Insider Own4.10% Shs Outstand61.30M Perf Week4.45%
Market Cap3.82B Forward P/E- EPS next Y-1.13 Insider Trans-37.73% Shs Float44.15M Perf Month17.54%
Income-65.20M PEG- EPS next Q-0.34 Inst Own70.80% Short Float4.67% Perf Quarter39.42%
Sales33.80M P/S113.15 EPS this Y-28.00% Inst Trans8.50% Short Ratio3.05 Perf Half Y103.03%
Book/sh0.98 P/B63.66 EPS next Y-11.30% ROA-30.70% Target Price59.20 Perf Year428.28%
Cash/sh3.00 P/C20.82 EPS next 5Y- ROE-100.50% 52W Range6.16 - 63.78 Perf YTD57.75%
Dividend- P/FCF- EPS past 5Y2.10% ROI-68.00% 52W High-2.17% Beta2.05
Dividend %- Quick Ratio3.20 Sales past 5Y- Gross Margin- 52W Low912.82% ATR3.58
Employees82 Current Ratio3.20 Sales Q/Q-27.70% Oper. Margin- RSI (14)65.41 Volatility5.97% 6.75%
OptionableYes Debt/Eq0.40 EPS Q/Q-55.10% Profit Margin- Rel Volume0.97 Prev Close60.38
ShortableYes LT Debt/Eq0.40 EarningsMay 11 AMC Payout- Avg Volume675.19K Price62.39
Recom1.50 SMA2011.24% SMA5028.10% SMA200106.18% Volume653,782 Change3.33%
May-27-20Initiated Wells Fargo Overweight $79
May-12-20Reiterated H.C. Wainwright Buy $60 → $69
Jan-24-20Reiterated H.C. Wainwright Buy $40 → $60
Nov-26-19Reiterated Piper Jaffray Overweight $17 → $54
Nov-26-19Reiterated H.C. Wainwright Buy $23 → $40
Mar-27-19Upgrade B. Riley FBR Neutral → Buy $12.50 → $22
Feb-11-19Initiated Piper Jaffray Overweight $20
Sep-07-18Initiated B. Riley FBR Neutral $12.50
Aug-14-18Downgrade JP Morgan Overweight → Neutral
Jun-28-18Initiated Raymond James Strong Buy
May-02-18Initiated H.C. Wainwright Buy $20
Feb-21-17Initiated JMP Securities Mkt Outperform
May-18-15Upgrade JP Morgan Neutral → Overweight
May-20-13Reiterated Stifel Buy $16 → $20
Nov-14-12Initiated Stifel Nicolaus Buy $16
May-29-20 01:38PM  Top Small Cap Stocks for June 2020 Investopedia
May-18-20 08:30AM  ChemoCentryx and VFMCRP Announce Topline Data from Phase II LUMINA-1 Trial of CCX140 in Focal Segmental Glomerulosclerosis (FSGS) GlobeNewswire +8.72%
May-16-20 10:49AM  Analysts Have Just Cut Their ChemoCentryx, Inc. (NASDAQ:CCXI) Revenue Estimates By 11% Simply Wall St.
May-14-20 06:53AM  ChemoCentryx, Inc. (NASDAQ:CCXI) Just Reported And Analysts Have Been Cutting Their Estimates Simply Wall St.
May-12-20 01:30PM  ChemoCentryx Inc (CCXI) Q1 2020 Earnings Call Transcript Motley Fool
09:30AM  Edited Transcript of CCXI earnings conference call or presentation 11-May-20 9:00pm GMT Thomson Reuters StreetEvents
May-11-20 07:55PM  ChemoCentryx (CCXI) Reports Q1 Loss, Misses Revenue Estimates Zacks
04:05PM  ChemoCentryx Reports First Quarter 2020 Financial Results and Recent Highlights GlobeNewswire
07:00AM  Is There An Opportunity With ChemoCentryx, Inc.'s (NASDAQ:CCXI) 47% Undervaluation? Simply Wall St.
May-04-20 08:30AM  ChemoCentryx to Hold First Quarter 2020 Financial Results Conference Call on Monday, May 11, 2020 GlobeNewswire +6.27%
Apr-27-20 12:31PM  Analysts Estimate ChemoCentryx (CCXI) to Report a Decline in Earnings: What to Look Out for Zacks
Apr-22-20 12:00PM  Here's Why Momentum Investors Will Love ChemoCentryx (CCXI) Zacks
Apr-07-20 12:00PM  ChemoCentryx (CCXI) Upgraded to Buy: What Does It Mean for the Stock? Zacks
Apr-05-20 01:17AM  Edited Transcript of CCXI earnings conference call or presentation 10-Mar-20 9:00pm GMT Thomson Reuters StreetEvents
Mar-31-20 04:52PM  5 Guru Stocks That Beat the Market GuruFocus.com
Mar-16-20 09:47AM  Why ChemoCentryx (CCXI) Stock Might be a Great Pick Zacks -22.52%
Mar-12-20 07:00AM  ChemoCentryx, Inc. Just Reported Full-Year Earnings And Analysts Are Lifting Their Estimates Simply Wall St. -5.90%
Mar-10-20 05:25PM  ChemoCentryx (CCXI) Reports Q4 Loss, Tops Revenue Estimates Zacks
04:05PM  ChemoCentryx Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Highlights GlobeNewswire
03:00PM  ChemoCentryx, Inc. to Host Earnings Call ACCESSWIRE
Mar-03-20 08:30AM  ChemoCentryx to Hold Fourth Quarter and Full Year 2019 Financial Results Conference Call on Tuesday, March 10, 2020 GlobeNewswire
Mar-02-20 12:30PM  ChemoCentryx (CCXI) Expected to Beat Earnings Estimates: Should You Buy? Zacks
Feb-19-20 08:30AM  ChemoCentryx to Present at the 9th Annual SVB Leerink Global Healthcare Conference GlobeNewswire
Jan-10-20 06:00PM  Biotechs punch up talking points leading into big Union Square conference American City Business Journals
05:01AM  Did The Underlying Business Drive ChemoCentryx's (NASDAQ:CCXI) Lovely 423% Share Price Gain? Simply Wall St.
Jan-09-20 08:30AM  ChemoCentryx Announces Credit Facility of Up to $100 Million with Hercules Capital GlobeNewswire
Jan-08-20 08:30AM  ChemoCentryx to Present at the 38th Annual JP Morgan Healthcare Conference GlobeNewswire
Dec-11-19 03:58PM  Hedge Funds Dropped The Ball On ChemoCentryx Inc (CCXI) Insider Monkey
Dec-01-19 09:30AM  The Week Ahead In Biotech: ASH 2019 Gets Underway, Biogen's Aducanumab Data And More Benzinga
Nov-29-19 11:24AM  The Zacks Analyst Blog Highlights: Intercept, CymaBay, Amgen, Global Blood Therapeutics and ChemoCentryx Zacks
Nov-28-19 09:00AM  ChemoCentryx (CCXI) Upgraded to Buy: What Does It Mean for the Stock? Zacks
Nov-27-19 10:15AM  Company News For Nov 27, 2019 Zacks
10:09AM  Biotech Stock Roundup: CBAY Falls, CCXI Gains, Amgen Acquires Otezla & More Zacks
08:52AM  ChemoCentryx Up on Encouraging Rare Disease Candidate Data Zacks
07:26AM  The Daily Biotech Pulse: Tonix Says No Surprises In FDA Meeting Minutes, Aravive Offering, FDA Nod For Qiagen Benzinga
07:23AM  Drug maker ChemoCentryx shares rocket on blockbuster potential in rare autoimmune disease MarketWatch
Nov-26-19 02:03PM  ChemoCentryx (CCXI) Stock Could Hit $40, Says Analyst TipRanks +281.27%
10:07AM  These stocks and ETFs will help investors survive a not great year, says top Wall Street strategist MarketWatch
08:42AM  Benzinga Pro's Top 5 Stocks To Watch For Tues., Nov. 26, 2019: BBY, CCXI, PANW, DLTR, DE Benzinga
08:30AM  ChemoCentryx to Present at the 31st Annual Piper Jaffray Healthcare Conference GlobeNewswire
08:14AM  Dow Jones Futures: Palo Alto Networks Dives, Nutanix Soars; This Biotech Quadruples Investor's Business Daily
08:06AM  The Daily Biotech Pulse: ChemoCentryx Triples On Data Readout, Global Blood Given FDA Nod, Positive Safety Review For Genfit's NASH Drug Benzinga
07:00AM  Market Morning: CBD Warning, Chemocentryx Win, Huge Tory Majority, Amazon Injuries Market Exclusive
01:00AM  VFMCRP and ChemoCentryx Announce Positive Topline Data From Pivotal Phase-III ADVOCATE Trial Demonstrating Avacopans Superiority Over Standard of Care in ANCA Associated Vasculitis TEST Business Wire Releases
01:00AM  VFMCRP and ChemoCentryx Announce Positive Topline Data From Pivotal Phase-III ADVOCATE Trial Demonstrating Avacopans Superiority Over Standard of Care in ANCA Associated Vasculitis Business Wire
Nov-25-19 06:11PM  ChemoCentryx stock quadruples after 'transformational' vasculitis study MarketWatch
04:05PM  ChemoCentryx and VFMCRP Announce Positive Topline Data from Pivotal Phase III ADVOCATE Trial Demonstrating Avacopans Superiority Over Standard of Care in ANCA-Associated Vasculitis GlobeNewswire
08:54AM  Are Options Traders Betting on a Big Move in ChemoCentryx (CCXI) Stock? Zacks
Nov-20-19 05:32PM  Plans filed for massive biotech campus in San Carlos American City Business Journals
Nov-17-19 02:41AM  Edited Transcript of CCXI earnings conference call or presentation 4-Nov-19 10:00pm GMT Thomson Reuters StreetEvents
Nov-11-19 08:33AM  How Should Investors React To ChemoCentryx, Inc.'s (NASDAQ:CCXI) CEO Pay? Simply Wall St.
Nov-05-19 08:30AM  Presentations at ASN Kidney Week 2019 Highlight Breadth of ChemoCentryx Platform in Treatment of Complement 3 Glomerulopathy (C3G) and Focal Segmental Glomerulosclerosis (FSGS) GlobeNewswire +6.84%
Nov-04-19 06:45PM  ChemoCentryx (CCXI) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:05PM  ChemoCentryx Reports Third Quarter 2019 Financial Results and Recent Highlights GlobeNewswire
Oct-30-19 06:59PM  ChemoCentryx Inc (CCXI) Is Burning These Hedge Funds Insider Monkey +5.65%
Oct-28-19 08:30AM  ChemoCentryx to Hold Third Quarter 2019 Financial Results Conference Call on Monday, November 4, 2019 GlobeNewswire
Sep-24-19 08:30AM  ChemoCentryx to Host R&D Day on October 1, 2019 GlobeNewswire
Aug-29-19 08:30AM  ChemoCentryx to Present at Two Upcoming Investor Conferences GlobeNewswire
Aug-17-19 06:09AM  Edited Transcript of CCXI earnings conference call or presentation 5-Aug-19 9:00pm GMT Thomson Reuters StreetEvents
Aug-08-19 10:19AM  ChemoCentryx Inc (CCXI) Q2 2019 Earnings Call Transcript Motley Fool
Aug-05-19 07:25PM  ChemoCentryx (CCXI) Reports Q2 Loss, Lags Revenue Estimates Zacks
04:05PM  ChemoCentryx Reports Second Quarter 2019 Financial Results and Recent Highlights GlobeNewswire
Aug-02-19 05:48PM  Longtime biotech to move up Peninsula to Alexandria's big San Carlos project American City Business Journals
Aug-01-19 08:30AM  ChemoCentryx to Present at the Canaccord Genuity 39th Annual Growth Conference GlobeNewswire
Jul-31-19 08:30AM  ChemoCentryx to Hold Second Quarter 2019 Financial Results Conference Call on Monday, August 5, 2019 GlobeNewswire
Jun-11-19 08:30AM  ChemoCentryx to Present at Two Upcoming Investor Conferences GlobeNewswire
Jun-06-19 07:37AM  The Daily Biotech Pulse: Takeda Pulls Plug On Amyloidosis Drug Trial, Chiasma Preps For Drug Launch With New CEO Appointment, Orchard Prices Offering Benzinga
May-20-19 09:00AM  ChemoCentryx (CCXI) Moves to Buy: Rationale Behind the Upgrade Zacks
May-11-19 02:05PM  Edited Transcript of CCXI earnings conference call or presentation 6-May-19 9:00pm GMT Thomson Reuters StreetEvents
May-09-19 11:07AM  Hedge Funds Have Never Been More Bullish On ChemoCentryx Inc (CCXI) Insider Monkey
May-07-19 01:29AM  ChemoCentryx Inc (CCXI) Q1 2019 Earnings Call Transcript Motley Fool
May-06-19 06:15PM  ChemoCentryx (CCXI) Reports Q1 Loss, Misses Revenue Estimates Zacks
05:12PM  ChemoCentryx: 1Q Earnings Snapshot Associated Press
04:05PM  ChemoCentryx Reports First Quarter 2019 Financial Results and Recent Highlights GlobeNewswire
Apr-29-19 08:30AM  ChemoCentryx to Hold First Quarter 2019 Financial Results Conference Call on Monday, May 6, 2019 GlobeNewswire
Apr-02-19 08:30AM  ChemoCentryx to Present at the H.C. Wainwright Global Life Sciences Conference GlobeNewswire
Mar-28-19 08:30AM  ChemoCentryx Appoints Rita Jain, M.D. to Board of Directors GlobeNewswire
Mar-19-19 08:41AM  ChemoCentryx (CCXI) Looks Good: Stock Adds 5.5% in Session Zacks +5.84%
Mar-18-19 10:04AM  Edited Transcript of CCXI earnings conference call or presentation 11-Mar-19 9:00pm GMT Thomson Reuters StreetEvents +5.79%
Mar-12-19 01:28AM  ChemoCentryx (CCXI) Q4 2018 Earnings Conference Call Transcript Motley Fool
Mar-11-19 05:30PM  ChemoCentryx (CCXI) Reports Q4 Loss, Lags Revenue Estimates Zacks
04:26PM  ChemoCentryx: 4Q Earnings Snapshot Associated Press
04:05PM  ChemoCentryx Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Highlights GlobeNewswire
Mar-04-19 08:30AM  ChemoCentryx to Hold Fourth Quarter 2018 Financial Results Conference Call on Monday, March 11, 2019 GlobeNewswire
Feb-26-19 08:20AM  New Research: Key Drivers of Growth for Ellie Mae, Spotify Technology SA, Bristow Group, Teradata, ChemoCentryx, and AgroFresh Solutions Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Feb-20-19 08:30AM  ChemoCentryx to Present at the 8th Annual SVB Leerink Global Healthcare Conference GlobeNewswire
Jan-24-19 08:30AM  ChemoCentryx Announces Withdrawal of Phase II-Based Conditional Marketing Authorization (CMA) Application for ANCA-Associated Vasculitis in Europe; Phase III ADVOCATE Trial Data Release Planned for Q4 2019 GlobeNewswire
Jan-02-19 08:30AM  ChemoCentryx to Present at the 37th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Nov-29-18 04:05PM  ChemoCentryxs Novel Small Molecule Antagonists of Checkpoint Inhibitors and Chemokine Receptors to be Presented at the American Association for Cancer Research (AACR) Tumor Immunology and Immunotherapy Conference GlobeNewswire
Nov-27-18 08:50AM  New Research Coverage Highlights Ralph Lauren, CECO Environmental, PRA Group, ChemoCentryx, SunCoke Energy Partners, and Delek US Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Nov-20-18 08:30AM  ChemoCentryx to Present at the 30th Annual Piper Jaffray Healthcare Conference GlobeNewswire
Nov-09-18 01:37AM  Edited Transcript of CCXI earnings conference call or presentation 8-Nov-18 10:00pm GMT Thomson Reuters StreetEvents -14.10%
Nov-08-18 07:00PM  ChemoCentryx (CCXI) Reports Q3 Loss, Lags Revenue Estimates Zacks
05:58PM  ChemoCentryx: 3Q Earnings Snapshot Associated Press
04:05PM  ChemoCentryx Reports Third Quarter 2018 Financial Results and Recent Highlights GlobeNewswire
Nov-01-18 08:30AM  ChemoCentryx to Hold Third Quarter 2018 Financial Results Conference Call on Thursday, November 8, 2018 GlobeNewswire +5.27%
Oct-30-18 10:33AM  Earnings Preview: ChemoCentryx (CCXI) Q3 Earnings Expected to Decline Zacks +9.91%
Oct-25-18 01:30PM  Presentations at ASN Kidney Week 2018 Highlight ChemoCentryx Platform in Treatment of ANCA-Associated Vasculitis and Focal Segmental Glomerulosclerosis (FSGS) GlobeNewswire
Oct-16-18 09:20AM  Analysis: Positioning to Benefit within ChemoCentryx, Armstrong Flooring, Kornit Digital, NewLink Genetics, Silvercorp Metals, and Halcon Resources Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire +9.00%
Sep-27-18 10:20PM  ChemoCentryx Determines Not to Proceed with Public Offering of Common Stock GlobeNewswire -18.04%
ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), which is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis; and Phase IIb clinical trial, the AURORA trial for the treatment of patients with moderate-to-severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy. In addition, the company is developing CCX140, an inhibitor of the chemokine receptor known as CCR2, which has completed a Phase II clinical trial in diabetic nephropathy and is being developed for patients with focal segmental glomerulosclerosis; CCX507, a second generation CCR9 inhibitor, which has completed Phase I clinical trial; and CCX872, a potent and selective inhibitor of CCR2, which is in phase Ib clinical trial for the treatment of patients with stage 3 and 4 pancreatic cancer. ChemoCentryx, Inc. was founded in 1996 and is headquartered in Mountain View, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Cappel Markus J.Chief Bus. Officer & TreasurerMay 26Option Exercise6.6219,612129,83195,859May 26 09:04 PM
Cappel Markus J.Chief Bus. Officer & TreasurerMay 26Sale60.3419,6121,183,42376,247May 26 09:04 PM
Tyree James LDirectorMay 23Option Exercise0.007,724013,069May 26 08:59 PM
Parker Geoffrey M.DirectorMay 23Option Exercise0.007,7240111,913May 26 08:55 PM
Cappel Markus J.Chief Bus. Officer & TreasurerMay 22Option Exercise6.6240,867270,540117,114May 26 09:04 PM
Cappel Markus J.Chief Bus. Officer & TreasurerMay 22Sale60.0640,8672,454,52576,247May 26 09:04 PM
Cappel Markus J.Chief Bus. Officer & TreasurerMay 21Option Exercise6.622,80018,53679,047May 26 09:04 PM
Cappel Markus J.Chief Bus. Officer & TreasurerMay 21Sale60.002,800167,98676,247May 26 09:04 PM
Schall Thomas J.President and CEOMay 12Option Exercise14.3135,865513,2282,304,422May 12 07:50 PM
Schall Thomas J.President and CEOMay 12Sale57.7535,8652,071,1002,268,557May 12 07:50 PM
Cappel Markus J.Chief Bus. Officer & TreasurerMay 11Option Exercise3.5734,222122,173110,469May 12 07:45 PM
Schall Thomas J.President and CEOMay 11Option Exercise14.3170,6081,010,4002,339,165May 12 07:50 PM
Schall Thomas J.President and CEOMay 11Sale55.5170,6083,919,7312,268,557May 12 07:50 PM
Cappel Markus J.Chief Bus. Officer & TreasurerMay 11Sale55.1134,2221,886,13576,247May 12 07:45 PM
Cappel Markus J.Chief Bus. Officer & TreasurerMay 08Option Exercise3.574,31215,39480,559May 12 07:45 PM
Schall Thomas J.President and CEOMay 08Option Exercise14.314,20160,1162,272,758May 12 07:50 PM
Schall Thomas J.President and CEOMay 08Sale55.014,201231,1152,268,557May 12 07:50 PM
Cappel Markus J.Chief Bus. Officer & TreasurerMay 08Sale50.014,312215,63976,247May 12 07:45 PM
Schall Thomas J.President and CEOMay 05Option Exercise14.318,851126,6582,277,408May 07 08:11 PM
KANAYA SUSAN MEVP, CFO and Sec.May 05Option Exercise8.1920,123164,807111,440May 06 08:19 PM
Cappel Markus J.Chief Bus. Officer & TreasurerMay 05Option Exercise3.578,86031,63085,107May 07 07:59 PM
KANAYA SUSAN MEVP, CFO and Sec.May 05Sale54.7320,1231,101,23791,317May 06 08:19 PM
Cappel Markus J.Chief Bus. Officer & TreasurerMay 05Sale55.018,860487,34576,247May 07 07:59 PM
Schall Thomas J.President and CEOMay 05Sale55.018,851486,8512,268,557May 07 08:11 PM
KANAYA SUSAN MEVP, CFO and Sec.May 04Option Exercise8.1954,877449,443146,194May 06 08:19 PM
KANAYA SUSAN MEVP, CFO and Sec.May 04Sale54.5754,8772,994,81991,317May 06 08:19 PM
Jain RitaDirectorMar 27Option Exercise0.005,251012,975Mar 31 07:10 PM
Parker Geoffrey M.DirectorMar 23Sale36.7030,0001,101,04949,600Mar 25 06:42 PM
Schall Thomas J.President and CEOMar 04Option Exercise14.3140,844584,4782,309,401Mar 05 07:03 PM
Schall Thomas J.President and CEOMar 04Sale50.3540,8442,056,6912,268,557Mar 05 07:03 PM
Schall Thomas J.President and CEOFeb 20Option Exercise14.3115,341219,5302,283,898Feb 21 07:24 PM
Schall Thomas J.President and CEOFeb 20Sale50.2115,341770,2962,268,557Feb 21 07:24 PM
Cappel Markus J.Chief Bus. Officer & TreasurerFeb 19Option Exercise8.1942,631349,148118,878Feb 21 07:05 PM
KANAYA SUSAN MEVP, CFO and Sec.Feb 19Option Exercise10.8624,200262,812118,380Feb 21 07:15 PM
Schall Thomas J.President and CEOFeb 19Option Exercise14.3163,340906,3952,331,897Feb 21 07:24 PM
Schall Thomas J.President and CEOFeb 19Sale50.5063,3403,198,5142,268,557Feb 21 07:24 PM
KANAYA SUSAN MEVP, CFO and Sec.Feb 19Sale50.1324,2001,213,22194,180Feb 21 07:15 PM
Cappel Markus J.Chief Bus. Officer & TreasurerFeb 19Sale50.3642,6312,146,69876,247Feb 21 07:05 PM
KANAYA SUSAN MEVP, CFO and Sec.Feb 13Option Exercise9.7645,300442,029139,480Feb 13 08:00 PM
KANAYA SUSAN MEVP, CFO and Sec.Feb 13Sale49.6145,3002,247,14794,180Feb 13 08:00 PM
KANAYA SUSAN MEVP, CFO and Sec.Feb 12Option Exercise9.692,50024,21396,680Feb 13 08:00 PM
KANAYA SUSAN MEVP, CFO and Sec.Feb 12Sale49.512,500123,77694,180Feb 13 08:00 PM
KANAYA SUSAN MEVP, CFO and Sec.Feb 11Option Exercise10.683,00032,04697,180Feb 13 08:00 PM
KANAYA SUSAN MEVP, CFO and Sec.Feb 11Sale49.503,000148,51094,180Feb 13 08:00 PM
Kwan Pui SanPrincipal Acctg OfficerFeb 11Sale49.1518,941930,888493Feb 13 07:50 PM
Cappel Markus J.Chief Bus. Officer & TreasurerFeb 06Option Exercise8.1936,850301,802113,097Feb 10 07:53 PM
Cappel Markus J.Chief Bus. Officer & TreasurerFeb 06Sale47.3136,8501,743,34076,247Feb 10 07:53 PM
Cappel Markus J.Chief Bus. Officer & TreasurerFeb 05Option Exercise8.1913,150107,69989,397Feb 05 08:02 PM
Cappel Markus J.Chief Bus. Officer & TreasurerFeb 05Sale47.0313,150618,45176,427Feb 05 08:02 PM
KANAYA SUSAN MEVP, CFO and Sec.Feb 04Option Exercise14.3199,6171,425,519193,797Feb 05 08:32 PM
Schall Thomas J.President and CEOFeb 04Option Exercise14.31119,5251,710,4032,388,082Feb 06 06:51 PM
Schall Thomas J.President and CEOFeb 04Sale45.18119,5255,400,7012,268,557Feb 06 06:51 PM
KANAYA SUSAN MEVP, CFO and Sec.Feb 04Sale45.1099,6174,492,22994,180Feb 05 08:32 PM
Cappel Markus J.Chief Bus. Officer & TreasurerFeb 03Option Exercise8.1948,471396,977124,718Feb 05 08:02 PM
KANAYA SUSAN MEVP, CFO and Sec.Feb 03Option Exercise14.313,83754,90798,017Feb 05 08:32 PM
KANAYA SUSAN MEVP, CFO and Sec.Feb 03Sale44.913,837172,31794,180Feb 05 08:32 PM
Cappel Markus J.Chief Bus. Officer & TreasurerFeb 03Sale44.4748,4712,155,52576,247Feb 05 08:02 PM
Cappel Markus J.Chief Bus. Officer & TreasurerJan 21Option Exercise8.191,25910,31177,506Jan 23 07:31 PM
Cappel Markus J.Chief Bus. Officer & TreasurerJan 21Sale44.001,25955,39276,247Jan 23 07:31 PM
KANAYA SUSAN MEVP, CFO and Sec.Jan 17Option Exercise14.2815,737224,724109,917Jan 17 07:49 PM
Schall Thomas J.President and CEOJan 17Option Exercise10.27105,7351,085,8982,374,292Jan 17 07:55 PM
Schall Thomas J.President and CEOJan 17Sale41.60105,7354,398,2722,268,557Jan 17 07:55 PM
KANAYA SUSAN MEVP, CFO and Sec.Jan 17Sale41.0315,737645,73094,180Jan 17 07:49 PM
Kwan Pui SanPrincipal Acctg OfficerJan 16Option Exercise8.3189,179740,881108,613Jan 17 07:36 PM
Cappel Markus J.Chief Bus. Officer & TreasurerJan 16Option Exercise7.1050,000355,000126,247Jan 17 07:42 PM
KANAYA SUSAN MEVP, CFO and Sec.Jan 16Option Exercise14.2847,261674,887141,441Jan 17 07:49 PM
Schall Thomas J.President and CEOJan 16Option Exercise10.2730,317311,3562,298,874Jan 17 07:55 PM
Schall Thomas J.President and CEOJan 16Sale41.0130,3171,243,1702,268,557Jan 17 07:55 PM
KANAYA SUSAN MEVP, CFO and Sec.Jan 16Sale40.9947,2611,937,10194,180Jan 17 07:49 PM
Cappel Markus J.Chief Bus. Officer & TreasurerJan 16Sale40.0750,0002,003,48076,247Jan 17 07:42 PM
Kwan Pui SanPrincipal Acctg OfficerJan 16Sale39.9189,1793,559,21619,434Jan 17 07:36 PM
Cappel Markus J.Chief Bus. Officer & TreasurerJan 14Option Exercise7.1030,145214,030106,392Jan 15 06:29 PM
Cappel Markus J.Chief Bus. Officer & TreasurerJan 14Sale37.7830,1451,138,90876,247Jan 15 06:29 PM
Cappel Markus J.Chief Bus. Officer & TreasurerJan 13Option Exercise7.1086,311612,808162,558Jan 15 06:29 PM
Cappel Markus J.Chief Bus. Officer & TreasurerJan 13Sale37.0986,3113,201,54076,247Jan 15 06:29 PM
Tyree James LDirectorJan 13Sale37.0630,0001,111,6865,345Jan 15 06:23 PM
Kwan Pui SanPrincipal Acctg OfficerJan 10Option Exercise3.571,0003,57020,434Jan 14 07:02 PM
Kwan Pui SanPrincipal Acctg OfficerJan 10Sale39.021,00039,01719,434Jan 14 07:02 PM
Kwan Pui SanPrincipal Acctg OfficerJan 06Option Exercise7.69122,912945,642142,346Jan 08 07:35 PM
Kwan Pui SanPrincipal Acctg OfficerJan 06Sale34.57122,9124,249,00819,434Jan 08 07:35 PM
Schall Thomas J.President and CEOJan 01Option Exercise0.0086,66702,315,522Jan 03 05:37 PM
KANAYA SUSAN MEVP, CFO and Sec.Jan 01Option Exercise0.0033,3340112,353Jan 03 05:27 PM
Cappel Markus J.Chief Bus. Officer & TreasurerJan 01Option Exercise0.0023,333089,033Jan 03 05:17 PM
KANAYA SUSAN MEVP, CFO and Sec.Dec 27Option Exercise9.7479,019769,48679,019Dec 30 07:14 PM
Cappel Markus J.Chief Bus. Officer & TreasurerDec 20Option Exercise6.1130,259184,83565,700Dec 23 07:34 PM
Parker Geoffrey M.DirectorDec 02Option Exercise6.0031,990191,940104,189Dec 04 06:10 PM
Cappel Markus J.Chief Bus. Officer & TreasurerNov 26Option Exercise11.36330,5243,753,261365,965Nov 27 07:11 PM
KANAYA SUSAN MEVP, CFO and Sec.Nov 26Option Exercise6.89311,6252,146,410402,942Nov 27 07:18 PM
Schall Thomas J.President and CEONov 26Option Exercise6.30279,1661,758,7462,508,021Nov 27 07:34 PM
Schall Thomas J.President and CEONov 26Sale31.55279,1668,808,1122,228,855Nov 27 07:34 PM
KANAYA SUSAN MEVP, CFO and Sec.Nov 26Sale31.51311,6259,818,23091,317Nov 27 07:18 PM
Cappel Markus J.Chief Bus. Officer & TreasurerNov 26Sale32.03330,52410,585,16735,441Nov 27 07:11 PM
KANAYA SUSAN MEVP, CFO and Sec.Oct 20Option Exercise0.0033,3340109,224Oct 22 06:29 PM
Parker Geoffrey M.DirectorMay 30Option Exercise6.0018,010108,06085,014Jun 03 06:17 PM
Parker Geoffrey M.DirectorMay 30Sale12.0012,815153,80672,199Jun 03 06:17 PM